Sage Therapeutics Inc. (SAGE)
NASDAQ (NMS) NASDAQ (NMS) Primary 
SAGE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Sage Therapeutics, Inc. and Encourages Investors to Contact the Firm
NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / December 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
Sage Therapeutics' pipeline setbacks continue as the phase II DIMENSION study on dalzanemdor for treating Huntington's disease fails to meet the primary goal.
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Sage Therapeutics' third-quarter 2024 earnings miss estimates. Stock falls in after-hours trading.
Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Katie Plante - Manager of Investor Relations Barry E. Greene - Chief Executive Officer Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Anupam Rama - J.P.
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.52. This compares to loss of $2.81 per share a year ago.
Contact Levi & Korsinsky by October 28, 2024 Deadline to Join Class Action Against Sage Therapeutics, Inc. (SAGE)
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
